Medicare Reimbursement Rate Targeted As Culprit For Drug Shortages
This article was originally published in The Pink Sheet Daily
Shortages of sterile injectables stem in part from changes to Part B reimbursement made in the Medicare Modernization Act in 2003, witnesses at a House hearing argue.
You may also be interested in...
Agency asks for comments to help it formulate a strategic plan to mitigate and prevent drug shortages, including ideas for incentives to increase manufacturing capacity and promote increased quality.
FDA officials state in journal article that manufacturers are not incentivized to ensure quality and base competition entirely on price.
Sterile injectable products with three or fewer manufacturers would get better federal reimbursement rates in an effort to attract more producers to the market; H.R. 6611 was modeled after a similar proposal from Sen. Orrin Hatch, R-Utah.